全球髓系白血病治疗市场 – 行业趋势及 2030 年预测

髓系白血病治疗市场分析和规模

为了应对血癌病例的增加，髓系白血病 (AML) 治疗不断涌现。在几种类型的白血病中，急性淋巴细胞白血病 (ALL) 通常见于儿童和年轻人，主要在 2 至 5 岁年龄段；不过，髓系白血病 (AML) 治疗在成年人中更为常见。不同性别、年龄和种族的患者中，白血病发病率各不相同，这些差异主要与环境暴露水平以及遗传因素有关。COVID-19 也对市场增长产生了重大影响。

Data Bridge Market Research 分析了 2023-2030 年预测期内髓系白血病治疗市场的增长率。预计到 2030 年，市场规模将达到 343 亿美元，2022 年为 160 亿美元，预计在 2023 年至 2030 年预测期内的复合年增长率为 10%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

髓系白血病治疗市场范围和细分

Market Definition

Myeloid leukemia is a kind of cancer of that affects blood and bone marrow. Growing diagnoses of myeloid leukemia which is caused because of exposure to carcinogens which are present everywhere, is leading to increased number of leukemia patients. Symptoms include easy bruising, breathlessness, fatigue, and bleeding. Higher risk factors such as carcinogens, bold disorders, and genetics increase the market expansion.

Myeloid Leukemia Treatment Market Dynamics

Drivers

• Huge Incidence of Myeloid Leukemia

There were around 61,780 new cases of leukemia and 22,840 mortalities in the U.S. in the year 2019. The number of myeloid leukemia treatment cases was expected at 21,450, in which adults held a major portion of the patient population. The growing incidence and increased death rate in the U.S. and other countries are building the way for increased uptake of associated therapies. It has been witnessed that 44% of acute myeloid leukaemia cases in the U.K. are in females, and 56% are in males. This factor boosts the market growth.

• Increase in Elderly Population

The elderly population is anticipated to increase the patient population worldwide, which boots the market in the forecast period 2023-2030. As per the records of the WHO, the global elderly population is anticipated to reach about 2 billion by 2050 from 617 million in 2015. The possibility of getting infected with several types of cancer also rises in this population. This factor will incease the demand of the treatment processes. This boost the market growth.

Opportunities

• Increase in usage in Hospitals

Hospitals and specialty clinics are the biggest end user of the leukemia treatment market and it is increasing because of the development of more and more hospitals. In addition to this, healthcare companies are also launching new and improved formulations of drugs for reducing the basal cell carcinoma cases. Thus, this factor will lead the market growth.

• Increased Technological Advancements

Traditional options for this diseased condition are unable to control relapse and are associated with several side-effects such as tissue damage, nausea and loss of appetite. These issues are increasing companies' focus on numerous advanced approaches such as serine-threonine protein kinases, stem cell transplant and pipeline drugs. There are numerous upcoming therapies such as immunotoxins, farnesyltransferase inhibitors, alkylating agents, FMS-like tyrosine kinase 3 inhibitors, monoclonal antibodies and multi-drug-resistant modulators that are going to contribute in the betterment of the patient condition. This creates more opportunity in the market.

Restraints/Challenges

• High Cost of Treatment

The increased expenditure of the treatment methods impede the market growth. Cost is a major factors that impacts the selection of treatment. Therefore, the high cost of myeloid leukemia treatment drugs is projected to hinder the growth of the market. Additionally, in an article published by American Society of Clinical Oncology Journal in 2020, the total annualized costs for CML was around US$ 82,054, more than those for hematologic malignancies (HEM) US$ 74,993 in the U.S. Thus, this factor hampers the market growth.

This myeloid leukemia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the myeloid leukemia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2022, the US FDA granted the company orphan drug designation for its pipeline compound OM-301 designated for the treatment of myeloid leukemia treatment (AML). It is developed by Oncolyze Inc.
• In 2021, the European Commission granted Orphan Drug Designation to SNDX-5613. It is a highly selective oral menin inhibitor for treating patients suffering from myeloid leukemia treatment (AML). It is developed by Syndax Pharmaceuticals Inc.

Global Myeloid Leukemia Treatment Market Scope

The myeloid leukemia treatment market is segmented on the basis of type, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Acute myeloid leukemia (AML)
• Chronic myeloid leukemia (CML)
• Others

Treatment Type

• Targeted Therapy
• Chemotherapy
• Cytarabine
• 蒽环类药物
• 烷化剂
• 抗代谢药物
• 酪氨酸激酶抑制剂
• 免疫疗法
• 激素治疗
• 其他的

给药途径

• 口服
• 肠外
• 其他的

最终用户

• 医院
• 家庭护理
• 专业中心
• 其他的

分销渠道

• 医院药房
• 网上药店
• 零售药店

 髓系白血病治疗市场区域分析/见解

对髓性白血病治疗市场进行了分析，并按类型、治疗类型、给药途径、分销渠道和最终用户提供了市场规模洞察和趋势。

髓性白血病治疗市场报告涉及的主要国家 有北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于主要市场参与者专注于新技术，北美预计将拥有最高的市场增长。美国急性髓性白血病发病率不断上升，将导致更多人采用该疾病的治疗方法，因此预计将推动北美该市场的增长。

由于白血病发病率高，亚太地区占据市场主导地位。预计髓系白血病研发和产品发布的不断增加将进一步推动该地区市场的增长。例如，百时美施贵宝于 2020 年获得美国 FDA 批准使用 Onureg 继续治疗无法完成强化治愈疗法的急性髓系白血病成年患者。​

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和全球髓系白血病治疗市场份额分析

髓系白血病治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对髓系白血病治疗市场的关注有关。

髓系白血病治疗市场的主要参与者包括：

• F. Hoffmann-La Roche Ltd.（瑞士）
• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（以色列）
• 赛诺菲（法国）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 诺华公司（瑞士）
• 拜耳公司（德国）
• 默克公司（美国）
• Cipla Inc.（美国
• 雅培（美国）
• AbbVie Inc.（美国）
• 太阳制药工业有限公司 (印度)
•  Aurobindo Pharma（印度）
• 鲁冰花（印度）
• Hikma Pharmaceuticals PLC（英国）
• 费森尤斯卡比公司（德国）
• Viracta Therapeutics, Inc.（英国）

SKU-52897